Full data support the potential of obicetrapib to address unmet medical need for millions of patients who cannot achieve their LDL-C targets with high-intensity statin therapy (HIS) alone Treatment
- Leading institutional investors commit approximately $235 million through an oversubscribed and upsized private investment in public equity ("PIPE") led by Frazier Healthcare Partners and Bain Capital